The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.
about
The factor VIII C1 domain contributes to platelet bindingPhosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a miceEffects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.Entactin: structure and function.Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain.Molecular mechanisms of mild and moderate hemophilia A.Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutationsThe influence of von Willebrand factor on factor VIII activity measurementsCharacterization of a genetically engineered inactivation-resistant coagulation factor VIIIaFine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain.Clearance mechanisms of von Willebrand factor and factor VIII.Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.Blood Clotting Factor VIII: From Evolution to Therapy.On the versatility of von Willebrand factorCan we improve on nature? "Super molecules" of factor VIII.Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II.Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A.Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.FVIII-VWF dos-à-dos.Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.Hypothesis for the control of clotting factor VIII inhibitory antibodies by decreasing potency of helper T-cell-recognized epitopes in factor VIII.Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
P2860
Q30481062-348C6F61-C38F-4477-9E84-09EB10F279DCQ33954639-BA7CB73E-65E3-4BA5-99F5-CE1841689435Q34099771-98D24F08-A06C-47BE-9862-2D77BCE9E5FFQ34157138-79CBC5D7-8AA3-448F-8D41-79C990E843C5Q34404185-81B1BA6F-67DB-4D1D-A0DA-08CC902E3674Q34451013-581A6EE4-6581-411C-9334-28BDB5D9765DQ35181733-A40EC683-6DC1-4B69-BBD4-48669E9769D4Q35881803-4E48AADA-06C7-4880-B2FC-8AB8E6F91F41Q36091335-48F8D018-68F8-4A4F-9508-06B4C990C6C8Q36621449-342B5A32-D282-4DDD-8A8E-16DCF6763036Q36676404-C0F71D34-DC1D-4E35-8873-0F8DFBBE1A85Q36787433-130A175D-55F1-4695-BE04-9440BFCB30C6Q37424095-4AB738F3-467E-44DD-885D-6FE94C9583F9Q37497557-BECFCFAC-E9C4-4184-B849-513C9134F813Q38118763-C94AB736-054A-423C-B882-3B2C25CA8FFCQ38128303-D8DDBD65-8962-4BD2-B5B8-49890838D249Q40830151-2D695C02-8884-4E21-A45E-7762D60517B4Q41258205-E4556274-D0C5-4CE5-A4EC-271B622CE7D5Q41676536-7086842E-C32C-4F27-94FF-4EC428DDA47BQ41695401-50632C4B-DC35-4160-96C1-F2BA5911971AQ41695610-E93F38F4-E9CD-40EF-A7A7-940223AD28BFQ41721581-0229E0BC-6F20-4062-ADFA-451C02B403BFQ41828726-9469EDF6-0795-4E22-8773-FEB738F9883CQ41850873-20CC74BB-9196-4E41-9F88-201A15767D2BQ42213583-9307EE97-77D7-422B-9E09-6C4E84EB941CQ42793239-B492CFDD-E942-4C07-8544-E424DC29F8BEQ45873498-1027EBCD-E6EE-4F14-9C76-0E8EC82AF192Q45875845-1492761A-68CC-4667-9FB2-1E3AB0E68CFEQ45878358-D4BC386C-B515-416E-AC83-C3188E5C6874Q45878768-6AFC6779-41B0-4CFA-BC25-5A20C7B2BB63Q45879587-1D380D29-97FA-4E37-99C0-90DE7861B0E7Q45886092-DD6B6ADE-9429-470A-AEBA-9D20C2450D67Q50959137-1D4AB6D0-762F-467C-9B1B-E77AA0E84569
P2860
The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
The interaction between human ...... y binding site on factor VIII.
@en
type
label
The interaction between human ...... y binding site on factor VIII.
@en
prefLabel
The interaction between human ...... y binding site on factor VIII.
@en
P2093
P2860
P356
P1433
P1476
The interaction between human ...... y binding site on factor VIII.
@en
P2093
Brodniewicz-Proba T
Van Mourik JA
Verbeet MP
P2860
P304
P356
10.1042/BJ2570679
P407
P577
1989-02-01T00:00:00Z